Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
Public ClinicalTrials.gov record NCT00050596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Study Comparing 4 Monthly Doses of MDX-010 (CTLA-4) as a Single Agent or Used in Combination With a Single Dose of Docetaxel in Patients With Hormone-Refractory Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single dose of cytotoxic chemotherapy (docetaxel) in combination with MDX-010
Study identification
- NCT ID
- NCT00050596
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2002 (Type not available)
- Primary completion
- Nov 2004 (Actual)
- Completion
- Nov 2004 (Actual)
- Last update posted
- Jun 27, 2011
2002 – 2004
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Advanced Clinical Therapeutics | Tucson | Arizona | 85712 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| San Diego Uro-Research | San Diego | California | 92101 | — |
| LSU Health Science Center/ Stanley S. Scott Cancer Center (uptown campus) | New Orleans | Louisiana | 70112 | — |
| Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| University Urological Research Institute | Providence | Rhode Island | 02906 | — |
| Grand Strand Urology | Myrtle Beach | South Carolina | 29572 | — |
| Urology Associates of North Texas | Arlington | Texas | 76012 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Salt Lake Research | Salt Lake City | Utah | 84124 | — |
| Seattle Cancer Center Alliance | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00050596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2011 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00050596 live on ClinicalTrials.gov.